Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Making Decisions on Bladder Removal

September 27th 2017

What is BCG Immunotherapy?

September 27th 2017

Muscle Invasive Bladder Cancer

September 27th 2017

Detecting Bladder Cancer

September 27th 2017

The Warning Signs of Bladder Cancer

September 27th 2017

Expert Gives Updates on Kidney and Bladder Cancer

September 27th 2017

Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Check, Please! Checkpoint Inhibitors Show Promise in Bladder Cancer

September 14th 2017

Immunotherapies known as checkpoint inhibitors are so promising in bladder cancer that many patients want them as first treatments — before they’ve been proven in that setting.

Keytruda Bests Chemotherapy in Overall Survival Rates for Bladder Cancer

September 11th 2017

Keytruda (pembrolizumab) produced better overall survival (OS) rates than chemotherapy for patients with recurrent, advanced urothelial carcinoma.

Expert Discusses New Bladder Cancer Treatment Guidelines

September 1st 2017

Jonathan E. Rosenberg, M.D., discusses the implications of the new treatment guidelines for muscle-invasive bladder cancer.

The Importance of a Multidisciplinary Team in Building Bladder Cancer Guidelines

July 28th 2017

Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.

Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

July 28th 2017

Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Diane Zipursky Quale on Shared Decision Making for Bladder Cancer

July 14th 2017

Diane Zipursky Quale, co-founder of the Bladder Cancer Advocacy Network, discusses the importance of patients discussing their treatment options with their physician before undergoing surgery.

Frontline Keytruda Shows Benefit Bladder Cancer

June 26th 2017

For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.

Expert Discusses Urothelial Carcinoma's Newest Agent

June 20th 2017

Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.

Pre-Surgical Gemcitabine Plus Cisplatin Benefits Bladder Cancer

June 15th 2017

When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.

Combined Modality Treatment May Be OK as First Course of Treatment for Muscle-Invasive Bladder Cancer

June 7th 2017

Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.

Drug Combination Is Effective in Urothelial Carcinoma

June 6th 2017

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Combination Improves Progression-Free Survival in Urothelial Carcinoma

June 1st 2017

According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.

Marilu Henner: Acknowledging Symptoms is the First Stop on the Road to Health

June 1st 2017

Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.

Expert Discusses Reducing Recurrence Risk in Bladder Cancer

May 26th 2017

Edward Messing, M.D., discusses his recent paper which explored a possible way to reduce recurrence in some patients with bladder cancer.

Electronic Cigarettes May Still Pose Bladder Cancer Risk

May 24th 2017

Though deemed "safer" than normal cigarettes, electronic cigarettes may still pose a risk for bladder cancer.

Expert Discusses Urothelial Carcinoma Approval

May 23rd 2017

Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.

FDA Approves Keytruda Approved for Urothelial Carcinoma

May 18th 2017

Keytruda (pembrolizumab) was granted an approval by the Food and Drug Administration (FDA) to treat some patients with locally advanced or metastatic urothelial carcinoma.

Sponsored Content: Grandmother With Advanced Bladder Cancer Finds Hope When Options Were Limited

May 17th 2017

Bladder cancer is the sixth most common cancer in the U.S.

FDA Approves Bavencio for Bladder Cancer

May 9th 2017

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

FDA Approves Imfinzi for Bladder Cancer

May 1st 2017

The Food and Drug Administration has granted accelerated approval for durvalumab for treatment of patients with bladder cancer.

Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer

April 18th 2017

The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

The Future of Immunotherapy for Urothelial Carcinoma Treatment

April 7th 2017

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

Advancing Immunotherapy Impact in Bladder Cancer

March 17th 2017

In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.

My New Life With Cancer

March 13th 2017